,27 Anti-inflammatory therapy with canakinumab, or colchicine but not methotrexate has been successful in reducing the risk of CV events in individuals with a previous myocardial infarction, associated with reductions in CRP.6 This evidence concerns the gene CRP and myocardial infarction.